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2000.—The thymus exhibits a pattern of aging oriented to-
ward a physiological involution. The structural changes start
with a steady decrease of thymocytes, whereas no major
variations occur in the number of thymic epithelial cells
(TEC). The data concerning the role of hormones and neu-
ropeptides in thymic involution are equivocal. We recently
demonstrated the presence of somatostatin (SS) and three
different SS receptor (SSR) subtypes in the human thymus.
TEC selectively expressed SSR subtype 1 (sst1) and sst2A. In
the present study we investigated whether SSR number is
age related in the thymus. Binding of the sst2-preferring
ligand 125I-Tyr3-octreotide was evaluated in a large series of
normal human thymuses of different age by SSR autoradiog-
raphy and ligand binding on tissue homogenates. The score
at autoradiography and the number of SSR at membrane
homogenate binding (Bmax) were inversely correlated with
the thymus age (r 5 20.84, P , 0.001; r 5 20.82, P , 0.001,
respectively). The autoradiographic score was positively cor-
related with the Bmax values (r 5 0.74, P , 0.001). Because
the TEC number in the age range considered remains un-
changed, the decrease of octreotide binding sites might be
due to a reduction of sst2A receptor number on TEC. The
age-related expression of a receptor involved mainly in con-
trolling secretive processes is in line with the evidence that
the major changes occurring in TEC with aging are related to
their capabilities in producing thymic hormones. In conclu-
sion, SS and SSR might play a role in the involution of the
human thymus. These findings underline the links between
the neuroendocrine and immune systems and support the
concept that neuropeptides participate in development of
cellular immunity in humans.
octreotide
THE THYMUS, THE PRIMARY LYMPHOID ORGAN responsible for
differentiation and maturation of the specific T cell
repertoire, exhibits an aging behavior that is unique
because of its irreversible physiological involution (16).
This phenomenon is characterized by a progressive
structural change of the gland, starting at an early
stage of life. Lipomatous atrophy is the most evident
age-related change in the thymus, although it repre-
sents the final state of the involution (33). The early
stages of this process are essentially characterized by a
steady decrease in the number of thymocytes, the lym-
phoid cellular component, and thymic dendritic cells,
whereas no major changes are found in the number of
thymic epithelial cells (TEC), which represent the most
relevant component of the thymic stroma (22). How-
ever, the human thymic epithelium is capable of un-
dergoing sequential stages of maturation in the post-
natal thymus (18). The factors regulating the
involution process of the thymus have not yet been
completely clarified. Particularly, contradictory hy-
potheses have been raised concerning the potential role
of hormones and neuropeptides in this process. For
instance, thymic involution is considered to be either
dependent on or independent of puberty (34, 36). Be-
cause several neuropeptides have been localized in
lymphoid tissues and because somatostatin (SS) may
influence cells of the immune system, we have recently
searched for the presence of SS and SS receptors (SSR)
in the normal human thymus (7). SS and three differ-
ent SSR subtypes (sst), sst1, sst2A and sst3, were ex-
pressed in human thymic tissue, although sst1 and
sst2A were expressed selectively on cultured TEC (7).
Moreover, SS and octreotide administration induced
an in vitro inhibition of TEC proliferation, which is
presumably mediated by receptors of the sst2A subtype
(7). These data support the concept of a modulatory
action of SS on cell functions within the thymus. In
addition, a functional role of SS and SSR in the invo-
lution process of the thymus can be hypothesized as
well. To evaluate whether the SSR pattern shows an
age-related change, we studied the binding of the sst2-
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preferring ligand 125I-Tyr3-octreotide in a large series
of normal human thymuses of different age. SSR den-
sity was determined both by SSR autoradiography and
by ligand binding studies on tissue homogenates. The
results were correlated with the chronological age of
the thymuses.
METHODS
Samples. Thymic tissues were removed from 30 patients
(15 males and 15 females, age ranging between 15 days and
21 yr) to allow adequate exposure of the heart during cardio-
vascular surgery. Samples from these thymuses were used in
the present study. The protocol was in accordance with the
Helsinki Doctrine on Human Experimentation, and informed
consent was obtained from patients or their parents. All
samples were histopathologically normal and were taken
fresh at the operation, quickly frozen on dry ice, and stored at
280°C for ligand binding on cryostat sections and membrane
homogenates. The 30 thymic tissue samples were divided
into five groups on the basis of arbitrary age ranges: group 1
(n 5 10), 0–12 mo; group 2 (n 5 5), 13–24 mo; group 3 (n 5
5), 25–72 mo; group 4 (n 5 5), 73–120 mo; group 5 (n 5 5),
.120 mo.
SS receptor binding on cryostat sections. Receptor autora-
diography was carried out as described by Visser-Wisse-
laar et al. (39). Briefly, 10-mm-thick cryostat (Jung
CM3000, Leica, Germany) sections of the tissue samples
were mounted onto precleaned gelatine-coated microscope
glass slides and stored at 280°C for $3 days before the
experiment to improve the adhesion of the tissue to the
slide. As radioligand, the SS analog 125I-Tyr3-octreotide
(Novartis Pharma, Basel, Switzerland) was used. Specific
activities of the radioligand amounted to ;2,000 Ci/mmol.
To wash out endogenous SS, the sections were preincu-
bated at room temperature for 10 min in 170 mM Tris z HCl
(pH 7.4). Thereafter, the sections were incubated for 60
min at room temperature in binding buffer (170 mM
Tris z HCl (pH 7.4), 5 mM MgCl2, 1% BSA, 40 mg/ml baci-
tracin) with 125I-Tyr3-octreotide (final concentration ;80–
160 pmol/l). Nonspecific binding was determined in a se-
quential section in the presence of excess unlabeled Tyr3-
octreotide (1 mM). The incubated sections were washed
twice for 5 min in binding buffer containing 0.25% BSA
and once in binding buffer without BSA. After a short wash
in distilled water to remove salts, the sections were air
dried and exposed to Kodak X-OMAT AR or Hyperfilm-3H
(Amersham) for 3–7 days in X-ray cassettes. Histology
was performed on hematoxylin-eosin-stained sequential
cryosections. A sample was considered positive for 125I-
Tyr3-octreotide binding when the signal obtained in a
control section was displaced by an excess of unlabeled
octreotide by .50% (12). The binding signals obtained
were analyzed densitometrically by means of a computer-
assisted image processing system and were quantified by
calculating the ratios between the regions of interest
delineated on the total (T) and nonspecific (NS) binding
sections. By use of the total-to-nonspecific (T/NS) ratios,
the amount of binding in every section was graded as
negative (0) for T/NS ranging from 0 to 1.9, positive (1)
for T/NS ranging from 2 to 3, and strongly positive (2) for
T/NS .3.
SS receptor binding on membrane homogenates. The
method of membrane isolation and the reaction conditions
were the same as those described by Reubi (28). Briefly,
membrane preparations (corresponding to 30–50 mg protein)
of tissue samples were incubated in a total volume of 100 ml
at room temperature for 60 min with increasing concentra-
tions of 125I-Tyr3-octreotide without and with excess (1 mm)
unlabeled octreotide in HEPES buffer (10 mM HEPES, 5 mM
MgCl2 and 0.02 g/l bacitracin, pH 7.6) containing 0.2% BSA.
After the incubation, 1 ml ice-cold HEPES buffer was added
to the reaction mixture, and membrane-bound radioactivity
was separated from unbound by centrifugation during 2 min
at 14,000 rpm in an Eppendorf microcentrifuge. The remain-
ing pellet was washed twice in ice-cold HEPES buffer, and
the final pellet was counted in a g-counter (1470 Wizard,
Wallac, Turku, Finland). Specific binding was taken to be
total binding minus binding in the presence of 1 mM unla-
beled octreotide.
Statistical analysis. Data are expressed as means 6 SE.
All data were analyzed by ANOVA to determine overall
differences between groups. When significant differences
were found, a comparison between groups was made using
the Newman-Keuls test. The comparison between categorical
data among the groups was analyzed with the Fisher’s exact
test. The correlation study was performed by use of nonlinear
or linear analysis calculating the Spearman or Pearson coef-
ficients, respectively, where appropriate. SSR binding data
were analyzed by the method of Scatchard. Receptor binding
studies were performed at least twice.
RESULTS
SSR binding on cryostat sections. Figure 1 shows an
exemplary case for each age group of the specific bind-
ing of the sst2 subtype-preferring ligand
125I-Tyr3-oct-
reotide on cryostat sections of human thymus. At au-
toradiography, the binding was not homogeneously
distributed but was localized mainly in the medullary
region of the thymuses (Fig. 1). With the use of a
three-point score, the amount of binding was graded as
strongly positive (2) in 8 out of 10 cases (80%) of group
1 and in 1 out of 5 cases (20%) of groups 2 and 3. The
binding was graded as positive (1) in 2 out of 10 (20%)
of group 1, in 4 out of 5 (80%) of groups 2 and 3, and in
1 out of 5 (20%) of group 4. The binding was graded as
faint or negative (0) in 4 out of 5 (80%) of group 4 and
in 5 out of 5 (100%) of group 5. The percentage of cases
with grades 2 and 1 was significantly higher in group 1
vs. groups 4 and 5 (P , 0.005) and in groups 2 and 3 vs.
groups 4 and 5 (P , 0.05). The mean values of T/NS
ratios displayed a progressive decrease with the in-
creasing age range in the five groups (Fig. 3A). The
mean T/NS values were significantly higher in group 1
than in groups 4 and 5 (P , 0.05). The decrease in the
T/NS values with the increasing age of the cases in the
five different groups shows an exponential rather than
a linear trend (Fig. 3A). Histology was normal in all of
the samples, and no major structural differences were
found between the different groups.
SSR binding on membrane homogenates. With the
use of 125I-Tyr3-octreotide, specific binding was detect-
able on membrane preparations of all thymic tissues,
except in four cases of group 4 and three cases of group
5. Scatchard analysis of the binding data revealed a
single class of high-affinity binding sites with an
average apparent dissociation constant (Kd) of 0.6 6
0.1 nm. The maximum binding capacity (Bmax) was
low, with an average of 18.5 6 3.6 fmol/mg membrane
protein, in the cases with detectable 125I-Tyr3-











octreotide binding. A sample saturation curve for each
group of with Scatchard analysis of the binding data is
shown in Fig. 2. The mean values of Bmax displayed a
progressive decrease with the increasing age range in
the five groups (Fig. 3B). The mean Bmax values were
significantly higher in group 1 than in groups 4 and 5
(P , 0.001). The decrease in the Bmax values with the
increasing age of the cases in the five groups shows an
exponential rather than a linear trend (Fig. 3B). As a
positive control for ligand binding, SSR-positive mouse
AtT-20 pituitary tumor cell membranes were used (Kd
of 0.19 6 0.03 nm; Bmax 705 6 64 fmol/mg membrane
protein). No specific binding was detectable on a
proven SSR-negative cell line and tissue (39).
Correlations. A significant correlation was found be-
tween ligand binding studies on cryostat sections or on
membrane homogenates and age of the thymus. In
detail, the T/NS ratios at autoradiography (r 5 20.84,
P , 0.001) and the Bmax values at membrane homog-
enate binding study (r 5 minus]0.82, P , 0.001) were
inversely correlated with the age of the thymus (Fig. 4,
A and B). In addition, the T/NS ratios at autoradiog-
raphy were correlated positively with the Bmax values
at membrane homogenate binding study (r 5 0.74, P ,
0.001; Fig. 4C). Conversely, no correlation was found
between the estimated Kd values and the age of the
thymuses and between gender and both T/NS and Bmax
values (data not shown).
DISCUSSION
The involution of the human thymus with age is a
complex phenomenon and remains poorly understood.
The human thymus interacts with products of endo-
crine glands throughout life, and although conflicting
results have been reported, thymic involution seems in
part dependent on age-related alterations in the inter-
action between the neuroendocrine activity and the
thymus itself (34, 36). Moreover, the intrathymic pro-
duction of hormones and neuropeptides and the pres-
ence of specific receptors represent an autocrine/para-
crine pathway, which, in addition to classical endocrine
circuits, might modulate the activities of both the lym-
phoid and stromal components of this organ (32). In
fact, TEC produce thymic peptides and other factors
known to modulate the main function of the gland,
namely the development of the T cell repertoire, and
many hormones and neuropeptides may participate to
this function by interacting via specific receptors with
developing immune cells and with TEC (4). However,
the role of neuropeptides and their receptors in thymic
involution is still debated.
SS is a well-characterized neuropeptide with a wide
spectrum of action, and recent insights have strongly
suggested that the thymus might belong to the list of
its target organs (7, 29, 30, 38). The five different SSR
subtypes recently cloned and characterized (24, 27)
show a tissue-specific distribution. The majority of
Fig. 1. Somatostatin receptor (SSR) binding in human thymuses of different ages: exemplary cases. Photomicro-
graph of SSR autoradiography: group 1 (age range 1–12 mo), group 2 (13–24 mo), group 3 (25–72 mo), group 4
(73–120 mo), group 5 (.120 mo). A: hematoxylin-eosin-stained section; B: autoradiogram showing total binding of
125I-Tyr3-octreotide; C: autoradiogram showing nonspecific binding (in the presence of 1 mm of Tyr3-octreotide).
Bar, 2 mm.






















SS-target tissues express multiple SSR, making it dif-
ficult to understand the functional role(s) of the indi-
vidual SSR subtypes. The best known SS analog, the
octopeptide octreotide, binds with high affinity to the
sst2 subtype (25). In the endocrine system, where they
have been better characterized, SSR subtypes are in-
volved in the control of hormone secretion and cell
proliferation, exerting mainly inhibitory effects via dis-
tinct mechanisms (15, 17). The sst2 subtype plays a
major role in this system. Whereas in the endocrine
system SSR activation leads to inhibitory effects, in the
Fig. 3. SSR binding in human thymuses of different ages. A: total-
to-nonspecific (T/NS) binding ratio values calculated at autoradio-
graphic binding study on cryostat sections; B: Bmax values detected
at binding studies on membrane homogenates of thymic tissues in
groups 1–5. Bars represent the value of T/NS ratios and Bmax
(fmol/mg protein) and are expressed as means 6 SE; *P , 0.05 and
P , 0.001 vs. group 1, respectively. Lines represent the exponential
trend of the changes in T/NS ratios and Bmax with the increasing age
in the 5 different groups of thymuses.
Fig. 4. SSR binding in human thymuses of different ages. A: corre-
lation between age and T/NS ratio values. B: correlation between age
and Bmax values; C: correlation between T/NS and Bmax values. T/NS
ratios and Bmax (fmol/mg protein) values detected at binding studies
on cryostat sections and membrane homogenates of thymic tissues of
the 30 cases distributed per age (mo).
Fig. 2. SSR binding in human thymuses of different ages: exemplary cases. Binding of 125I-Tyr3-octreotide to a
membrane homogenate preparation of human thymuses: A: group 1 [age, 3 mo; maximum binding capacity (Bmax),
54; dissociation constant (Kd), 0.8]; B: group 2 (age, 14 mo; Bmax, 18; Kd, 0.3); C: group 3 (age, 35 mo; Bmax, 8; Kd,
0.3); D: group 4 (age, 97 mo; Bmax, 2.7; Kd, 0.1); E: group 5 (age, 144 mo; Bmax, 1.1; Kd, 0.1). Saturation curves
indicate the specific binding (total minus nonspecific binding in presence of 1 mM of Tyr3-octreotide). Insets:
Scatchard analysis of the binding data; F: summary of the Scatchard analysis data. , Group 1; 3, group 2; n , group
3; F, group 4; {, group 5.











immune system, both stimulatory and inhibitory ef-
fects have been reported (6, 38). Moreover, very little is
known with respect to the cellular signaling mecha-
nisms coupled to SSR activation in immune cells (13).
In normal human thymus, we recently demonstrated
the presence of three different SSR subtypes, sst1,
sst2A, and sst3 (7). In TEC, sst1 and sst2A were selec-
tively expressed, and TEC seemed to produce SS, be-
cause SS mRNA was present in these cells (7). All
together, these findings pointed toward an important
role of the sst2A receptor in the human thymus, which
seems to be confirmed by the heterogeneity of the
expression of this subtype among thymic cells (7).
In the present study, we have found additional evi-
dence for a functional role of the sst2A receptor in the
thymus. This SSR subtype may be involved in the
processes linked to the thymic age-related changes,
because its number undergoes significant changes with
increasing age. In fact, using two different techniques,
we observed an inverse relationship between the num-
ber of binding sites for the sst2-preferring ligand
125I-
Tyr3-octreotide and the age of the thymus. The number
of 125I-Tyr3-octreotide-binding sites was significantly
higher in the younger subjects. This finding is in line
with the recently reported evidence of an in vivo thy-
mic uptake of 111In-DTPA-D-Phe1-octreotide in the
three youngest patients (ages 4, 5, and 16 mo) out of 11
who underwent SSR scintigraphy to evaluate abdomi-
nal or pelvic neuroblastoma (8). Conversely, no thymic
concentration of 111In-DTPA-D-Phe1-octreotide was
documented in the relatively older children of the same
series and in a series of adult patients with thymic
hyperplasia (19). In the present study, the ages of the
thymus were inversely correlated with both the results
of the autoradiographic studies on thymic cryostat sec-
tions and the Bmax values measured at the ligand-
binding studies on tissue homogenates of the corre-
sponding cases. Moreover, the score of the
autoradiography was positively correlated with the
values of the Bmax. Although autoradiography is a
semiquantitative method for the evaluation of the li-
gand binding, the Bmax value directly indicates the
density of binding sites for a specific ligand expressed
on cell membranes. Moreover, it should be pointed out
that, at the ligand binding on membrane homogenates,
the estimated Kd values were not correlated with thy-
mus age. This suggests that the change in the number
of SSR binding sites is not related to changes in recep-
tor affinity. Considering that sst2A is expressed mainly
on TEC in the medullary compartment of the human
thymus (7, 29, 30), it might appear that the reduction
of the number of binding sites is related to the decrease
in the number of sst2A-expressing cells. This seems
unlikely, however, because the number of TEC in the
age range considered in our study remains almost
unchanged (22, 33). In fact, little or no decrease in the
number of keratin-positive cells has been demon-
strated, whereas thymocytes especially, and to a much
lesser extent dendritic cells, decrease dramatically in
number during the aging process (22). During postna-
tal development, the thymic epithelium displays a
pathway of differentiation similar to that observed in
other epithelial organs throughout the human body
rather than a real change in the number of its cellular
elements (18). This observation supports the concept
that the thymic epithelium is capable of undergoing
sequential stages of maturation during fetal and post-
natal thymic development. Moreover, even considering
that, at a certain point, the number of TEC declines,
contributing to the significant reduction of the oct-
reotide-binding sites, we have observed a progressive
decrease of the number of octreotide-binding sites
starting after the first years of life when the number of
TEC is still unchanged. Because two different tech-
niques gave a comparable result, it is suggested that
the decrease in the number of sst2A occurs on TEC.
Although in cultured thymocytes no mRNA encoding
for SSR subtypes was detectable (Fig. 7), we have
recently demonstrated SSR binding on freshly isolated
thymocytes (5). Preliminary RT-PCR data have shown
the expression of sst2A and sst3 mRNAs in resting
thymocytes. However, sst3 seems to be the SSR sub-
type predominantly expressed in the heterogeneous
pool of T lymphoid cell precursors, whereas sst2A
mRNA expression is limited to a very small subset of
immature cortical thymocytes (unpublished observa-
tions). The recent evidence of a selective expression of
sst3 mRNA in peripheral human T lymphocytes (10) is
in line with our observation in thymocytes, which are
the natural precursors of circulating T cells. Although
the immature thymocytes are localized in the cortical
region of the human thymus, a contribution of their
loss to the decline of octreotide-binding sites cannot be
fully ruled out. However, it should play a minor role in
this phenomenon, because, according to the autoradio-
graphic pattern, the decline of octreotide-binding sites
occurs mainly in the medullary region of the thymus,
where TEC are the predominant cell type displaying
sst2A-binding.
sst2A is the SSR subtype involved in controlling se-
cretive processes in SS target cells. Thus the reduction
of this receptor on TEC might be in line with the
evidence that the major changes occurring in these
cells during aging are related more to their functional
capabilities in producing thymic hormones rather than
to modification in their number (22). The decrease in
sst2A receptor numbers might be related to the produc-
tion of substances modulating the thymus involution,
as well as the maturation of T cells. Which is the
factor(s) involved in regulating receptor expression
needs to be further investigated. However, in light of
studies in which stimulation of neuropeptide receptors
by their own ligand was shown to result in receptor
internalization (20, 21), it is possible that a downregu-
lation of sst2A receptors might occur as a consequence
of ligand-induced internalization. In fact, the sst2A re-
ceptor has been demonstrated to efficiently internalize
bound ligand in many cell systems (11, 14, 23). Fur-
thermore, it has been demonstrated in rat brain that
endogenous SS regulates cell surface sst2A receptors
(3). The presence of endogenous SS within the human
thymus (1, 7, 9, 26, 31, 35) might account for a regu-











lation of sst2A receptor expression on TEC by this
mechanism. Conformational changes and/or chemical
alterations of the internalized receptor might explain
why the exogenous ligand does not recognize its spe-
cific receptor (23). However, the influence of additional
factors, like cytokines or other neuropeptides, cannot
be ruled out either in such a complex organ. It is known
that hormones and neuropeptides can modulate TEC
physiology by exerting a pleiotropic action on thymic
stroma. In fact, glucocorticoid, thyroid, and pituitary
hormones can modulate extracellular matrix ligands
and receptors (32). Moreover, the expression of recep-
tors for neuropeptides, such as vasoactive intestinal
polypeptide, appears to be developmentally regulated
in several systems, including the thymus (2, 37).
In conclusion, the number of sst2A is inversely corre-
lated with the age of the human thymus. The receptor
itself and obviously SS might play a role in the invo-
lution of the thymus, consequently affecting the main
function of this organ. Although further studies are
required to clarify this complex but fascinating net-
work between the neuroendocrine and the immune
systems within the human thymus, our findings raise
the possibility that neuropeptides may participate in
the intrathymic maturation and differentiation of T
cell repertoire, which leads to the development of cel-
lular immunity in humans.
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